Member Info for amones

Pencil, any foreseeable direct (or indirect) benefits to Hutchmed from this news item?

Davey, loss of 70% of investment must be really hurting. Wondering about the opinions being expressed by investors in HK and mainland China. Is anyone over there raising questions about this utterly poor share price in spite of achievements in sales, licensing deal with Takeda, last week’s FDA approval for NDA review and the pipeline. As expressed on this forum, if short sellers are responsible for this kind of fall of share price, is it not the duty of the company’s IR office to come out with a statement to pacify the investors.

Deliberate attempts to persuade any remaining holders to give up. Who else, other than the shorting fund holders, have been selling?? Totally ridiculous.

The management are totally unconcerned about the market valuation. What are the institutional investors doing? Have they raised any questions?

Do the chinese investors, if any, still consider number 13 as auspicious? Here is an example to prove it otherwise.

what’s wrong with this stock?? gone down at hkse. never fails to disappoint, in spite of the fru*****inib nda news. are there any ulterior motives to make all holders to give up? takeda might have taken over the whole company by adding some extra change to the ex-china fru*****inib license deal.

Two important points regarding this NDA;

1. Going along with Takeda, a well established pharmaceutical company.

2. Supporting evidence includes “…FRESCO-2 is a global Phase III multi-regional clinical trial (MRCT) conducted in the U.S., Europe, Japan and Australia…”.

After the bad experience with Surufatinib, much better approach by the management. Well done.

Hong Kong exchange closed today due to a holiday.

Pencil, Takeda pharmaceuticals market valuation is much more bigger than that of Hutchmed, 50.76B and 2.11B respectively at close in NYSE.

Thank you pencil. That is very reassuring.

This company is badly in need of a full time and dedicated CEO.

It’s difficult to accurately identify if a trade is a sell or a buy. Websites like this make a guesstimate before marking the sales red or blue depending on the market quote. However, its quite worrying to see the sp dropping at all three exchanges since yesterday. Yesterday, during the first hour of trading at HKSE, sp spiked above 26 HK dollars. Following that period, it’s been red throughout.

Retrospectively, we can see one big mistake that happened while applying to the FDA for approval for Surufatinib, Clinical research data from studies which didn’t have any American patient population and going “solo”. That Failure (purely due to inexperience) at that significant moment lead to continuous downward spiral and the CEO “retiring” suddenly. A collaboration with another major player, would have provided the required preparation, knowledge and expertise while making that application. Hopefully, the ongoing “multi centre” studies are going in the correct direction and the management will get a major player on their side during the re-application process. Needless to say FDA has to be very cautious while approving a new therapy developed by a smaller pharmaceutical company based in China. The same would be different if the application also included an established major pharma.

What is on the agenda for this Friday’s AGM? Hopefully, there will be some good things to cheer up us, the longstanding (suffering) investors. Cornerstone investors who pumped vast sums of money should get more proactive. Let us se what comes out from the AGM.

I think it was Lauders who wrote here, few days ago, how badly the company has been missing a charismatic CEO like CH. 100% correct. Especially, at a time when a major pharma like AZN is talking about “making in China” that too in oncology sector. There are few posts about the value of HCM, in case of takeover or merger. Just one single drug’s (Fru*****inib) ex-China licence is worth nearly $1.4 billion. How much is it for the whole company? Major investors bought several millions of stocks paying more than the present sp. As per the previous post, they are still holding their shares. That is one bit of comforting matter.

Another encouraging news, acceptance for Fruquintinib as second line of therapy for gastric carcinoma. Takeda should certainly like to get approval for the same indication, ex-Chaina. Takeda management must have done a thorough study before going for the agreement with HCM for the ex-china license for Fruquintinib. That single agreement has a potential income of around $1.4 billion to HCM. Isn’t it intriguing why Takeda (or any other major pharma) should not be making a bid for the whole company? An offer of 5 times today’s market cap still comes to $ 15 billion. All the encouraging news about involvement of major players in China related business opportunities is indeed making long term investors more optimistic!

Pencil, perhaps a silly question, what’s this ‘auction’?

Management might have selected the auspicious New year day for announcing the Takeda deal. Not a great deal of enthusiastic response shown at NYSE, for a deal worth one billion, during last 3 days of trading. Has this ‘sub optimal’ nyse reaction affected HKSE when it reopened today after the holidays?
Suppose the same deal was announced on a different date, when HKSE fully functioning, market response would have been much better. In that case, HKSE trading would have taken the precedence in deciding the true value of the excellent deal.

At least, FDA can not “find faults” with this application as the supporting clinical studies were multi centred, unlike the case with Surufatinib.

That equals to more than 55 million ordinary shares! There was a drop in the sp towards end of the trading hours. If the majority of the trades were ‘offloading’ of any kind, sp at HKSE and AIM should have plummeted. Today has been another large volume trading (12 million ) at HKSE. HCM sp in AIM market has been in green zone, so far. Any interesting reasons behind the massive volumes?

Could someone please check the present holding and short status of major institutions. Wondering if the several millions of trades over the last few weeks has resulted any changes in those figures.

Thank you Davey. Do you know if Hutchmed still owns the commercial platform marketing other generic drugs?

CS, Thanks for a good assessment of the present status. A breakdown estimation of the commercial values of all the ‘marketable’ components and products in the pipeline is required. That would help the stock market/s to value the company more realistically. Let’s hope the company finds suitable partnerships it has been looking for, very soon. That should do a great deal of help in the progress of global multi centre studies, approval applications and marketing globally. Recovery in the share price, although small, is nice to watch.